Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IMMP
IMMP logo

IMMP Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Immutep Ltd (IMMP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.370
1 Day change
52 Week Range
3.530
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Immutep Ltd (IMMP) is not a strong buy at this time for a beginner investor with a long-term focus. The stock faces significant legal risks due to ongoing class action lawsuits, and its technical indicators do not suggest a strong upward trend. While there is an analyst upgrade with a high price target, the negative catalysts outweigh the positives, and no proprietary trading signals are present to indicate a strong buy opportunity.

Technical Analysis

The MACD is slightly positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 46.574, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.369, with resistance at 0.388 and support at 0.351. Overall, the technical indicators do not suggest a strong buy signal.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
3

Positive Catalysts

  • An analyst from Maxim upgraded the stock to Buy with a $1.50 price target, which is significantly higher than the current price.

Neutral/Negative Catalysts

  • The company is facing multiple class action lawsuits related to alleged securities violations and the failed TACTI-004 trial, creating significant legal and reputational risks. There are no significant hedge fund or insider trading trends to support confidence in the stock.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Maxim analyst Jason McCarthy upgraded Immutep to Buy from Hold with a $1.50 price target on 2026-06-17. However, no other recent analyst ratings or price target changes are noted.

Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
Wall Street analysts forecast IMMP stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.374
sliders
Low
12
Averages
12
High
12
Current: 0.374
sliders
Low
12
Averages
12
High
12
Maxim
Jason McCarthy
Hold
to
Buy
upgrade
$1.50
AI Analysis
2026-06-17
New
Reason
Maxim
Jason McCarthy
Price Target
$1.50
AI Analysis
2026-06-17
New
upgrade
Hold
to
Buy
Reason
Maxim analyst Jason McCarthy upgraded Immutep to Buy from Hold with a $1.50 price target.
Maxim
Maxim
Buy -> Hold
downgrade
2026-03-13
Reason
Maxim
Maxim
Price Target
2026-03-13
downgrade
Buy -> Hold
Reason
Maxim downgraded Immutep (IMMP) to Hold from Buy after the company's Phase 3 study with Merck (MRK) of eftilagimod alfa in patients in first line non-small cell lung cancer was halted for futility.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IMMP
Unlock Now

People Also Watch